



# Wanhai Medical

---

## A Decade of Dedication:

China's Premium Manufacturer & Expert in Self-Administration Devices.

Building 7, No.9-2 Changyang Road, West Taihu Sci-Tech Park,  
Wujin District, Changzhou, Jiangsu, China.

Tel: +86-519-85857533

Email: [sales@pen-injectors.com](mailto:sales@pen-injectors.com)

Web: [www.pen-injectors.com](http://www.pen-injectors.com)



**COST-EFFECTIVE  
EXCELLENCE**

Dedicated to five consecutive years  
of price reductions

# ► About Wanhai Medical

Wanhai Medical was founded in Changzhou, Jiangsu in 2016. For a decade, it has specialized in the R&D, manufacturing and sales of self-administration devices. The company has been awarded the national titles of “National High-Tech Enterprise” and “Specialized, Sophisticated and Innovative Enterprise”.

The company currently owns a production plant of 12,000-square-meters with over 350 employees. It has more than 50 senior R&D professionals graduated from renowned science and engineering universities, alongside over 20 members respectively in the regulatory registration, quality and sales teams. We have established a stable mass production capacity of 120 million disposable and reusable pen injectors annually. A new 40,000-square-meter factory is now under expansion. Once completed, it will become an automated and intelligent manufacturing base for pen injectors with a total annual capacity of 400 million units.

With Wanhai Medical vertically integrated industrial layout, consistently high standards, efficient customer service and support, exceptional value proposition, it has earned wide recognition in global markets.

To date, Wanhai Medical has served over 440 clients across more than 80 countries and territories worldwide with its products and integrated services.



Facility Size

**12,000sqm** (Current)  
**+ 40,000sqm** (Expanding)



Annual Capacity

**120M** (Current)  
**+ 310M** (Expanding)



Workforce

**350+**



Global Clients

**440+**



Countries & Regions

**80+**



# ► Accreditations & Honors

Wanhai Medical has obtained CE certification, ISO 13485 certification and MDSAP certification issued by TÜV SÜD, as well as NMPA Class II Medical Device License (Jiangsu Medical Products Administration), Pharmaceutical Packaging Filing (NMPA CDE). The company has also completed national pharmaceutical packaging material filing. Currently, we are in the application process for US FDA certification.

Wanhai Medical holds more than 110 product patents, together with product quality test reports issued by over 30 third-party testing institutions. Core product patents have undergone FTO searches by renowned patent agencies to ensure risk-free global sales without patent infringement.

With long-term and large-scale commercial verification, our products feature excellent performance, stable quality and high reliability.

## Corporate Recognition



National High-Tech Enterprise



Specialized, Sophisticated,  
and Innovative Enterprise

## International Certification



CE Certification (Issued by TÜV SÜD)



ISO 13485 Certification (Medical Device QMS)



MDSAP Certification



FDA Certification (Under Authentication)

## Domestic Certification



NMPA Class II Medical  
Device Registration



Pharmaceutical Packaging  
Material Certification

## Intellectual Property



110+ Patents for pen injector technologies.

## R&D Excellence



Core products cleared via freedom-to-operate analysis by leading IP agencies.




Senior R&D Engineers Advanced degrees from globally-recognized STEM universities.

# ► Manufacturing Excellence

Global Tier-1 raw material sourcing.

Leveraging fully automated smart manufacturing for a vertically integrated production system.



## TOOLING CENTER

50+ Advanced Mold Fabrication Systems



▲ Makino EDM



▲ Makino CNC



▲ Sodick WE



▲ Sodick EDM

## METROLOGY LAB



▲ Hexagon CMM(Coordinate Measuring Machine)



▲ Mitutoyo Projectors  
(Precision Optical Measurement)

## INJECTION MOLDING CENTER

70+ Sumitomo Demag Electric Molding Machines (e-mac)



▲ Cleanroom Molding Zone(Class 100,000) SE50-100 series



▲ Standard Molding Group 1 SE100-180 series



▲ Standard Molding Group 2 SE180-220 series




▲ Standard Molding Group 3 SE220 series

# SCREEN PRINTING & ASSEMBLY

Class 100,000 Cleanroom Environment | Fully Automated Production Line | Assembly with Inline QC Inspection



# QUALITY ASSURANCE LABORATORY



▲ QA Lab

▲ Nikon Vision Measurement System (VMS)

▲ Mitutoyo Optical Comparator

# ▶ Product Showcase

## Client-Driven Customization

We engineer Pen Injector to your exact specifications:

Color Schemes & Packaging Design | Dosing Mechanism Optimization | End-to-End URS Compliance Documentation

### WH-DC | Disposable Pen Injector



Application	Cartridge Size (mL)	Min. Deliverable Dose (mL)	Dosing Increments	Dosing Range (mL)
Semaglutide	3	0.0125	30	0-0.375
	3	0.0125	60	0-0.75
Tirzepatide	3	0.01	60	0-0.60
Liraglutide	3	0.01	30	0-0.30
	3	0.01	50	0-0.50
Teriparatide	3	0.005	16	0-0.08
Insulin Glargine, Insulin Aspart, Biphasic Insulin Aspart 30, Biphasic Insulin Aspart 25, NPH Insulin	3	0.01	60	0-0.60
Insulin Degludec and Liraglutide	3	0.01	50	0-0.50

### WH-DB | Disposable Pen Injector



Application	Cartridge Size (mL)	Min. Deliverable Dose (mL)	Dosing Increments	Dosing Range (mL)
Growth Hormone	1.5	0.02	25	0-0.50
Tirzepatide	3	0.01	60	0-0.60

WH-DE | Disposable Pen Injector



Application	Cartridge Size (mL)	Min. Deliverable Dose (mL)	Dosing Increments	Dosing Range (mL)
Semaglutide	3	0.01	74	0-0.74
	3	0.0125	30	0-0.375
	3	0.0125	60	0-0.75
	3	0.0156	48	0-0.75
Tirzepatide	3	0.01	60	0-0.60
Liraglutide	3	0.01	30	0-0.30
	3	0.01	50	0-0.50
Teriparatide	3	0.01	8	0-0.08
	3	0.005	16	0-0.08
Follicle-Stimulating Hormone (FSH)	3	0.0208	36	0-0.75
Insulin Glargine, Insulin Aspart, Biphasic Insulin Aspart 30, Biphasic Insulin Aspart 25, NPH Insulin	3	0.01	60	0-0.60
Insulin Degludec	3	0.01	80	0-0.80
Insulin Degludec and Liraglutide	3	0.01	50	0-0.50
Growth Hormone	3	0.0075	60	0-0.45

WH-DG | Multi-Dose Disposable Auto-Injector Pen



Application	Cartridge Size (mL)	Min. Deliverable Dose (mL)	Dosing Increments	Dosing Range (mL)
Semaglutide	1.5	0.01	37	0-0.37
	3	0.01	74	0-0.74
Tirzepatide	3	0.01	60	0-0.60
Insulin Degludec	3	0.01	80	0-0.80
Insulin Degludec and Liraglutide	3	0.01	50	0-0.50

WH-DF | Prefilled Syringe Disposable Auto-Injector Pen



Application	Refill(mL)	Dose Range(mL)
Tirzepatide	1	0.15-1.00
Semaglutide		
Adalimumab		
Alirocumab		
Ixekizumab		
Secukinumab		
Omalizumab		
Adrenaline	2.25	0.50-2.00
Sarilumab		
Omalizumab		
Fremanezumab		
Secukinumab		
Dupilumab		
Alirocumab		

UrgoPen | Disposable Auto-Injector Pen



Application	Cartridge Volume (mL)	Dosing Range (mL)
Growth Hormone	Customize 2.25	0.15-2.00

## WH-RA | Reusable Pen Injector



WH-RA2

WH-RA3

WH-RA4

Application	Cartridge Size (mL)	Min. Deliverable Dose (mL)	Dosing Increments	Dosing Range (mL)
Semaglutide	3	0.0125	30	0-0.375
	3	0.0125	60	0-0.75
Tirzepatide	3	0.01	60	0-0.60
Liraglutide	3	0.01	30	0-0.30
	3	0.01	50	0-0.50
Teriparatide	3	0.005	16	0-0.08
Insulin Glargine, Insulin Aspart, Biphasic Insulin Aspart 30, Biphasic Insulin Aspart 25, NPH Insulin	3	0.01	60	0-0.60
Insulin Degludec	3	0.01	80	0-0.80
Insulin Degludec and Liraglutide	3	0.01	50	0-0.50
Growth Hormone	3	0.0075	60	0-0.45

## WH-RG | Reusable Auto-Injector Pen



Application	Cartridge Size (mL)	Min. Deliverable Dose (mL)	Dosing Increments	Dosing Range (mL)
Semaglutide	5	0.02	50	0-1.00
Tirzepatide				
Liraglutide				
Teriparatide				
Insulin Glargine, Insulin Aspart, Biphasic Insulin Aspart 30, Biphasic Insulin Aspart 25, NPH Insulin				
Insulin Degludec				
Insulin Degludec and Liraglutide				
Growth Hormone				